Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy
原文开头
Junedh M. Amrute1,2,3,4†, In-Hyuk Jung1†, Tracy Yamawaki2, Wen-Ling Lin2,5, Andrea Bredemeyer1, Johanna Diekmann6, Sikander Hayat7, Xianglong Zhang2, Devin L. Wakefield2, Xin Luo2, Sidrah Maryam7, Gyu Seong Heo8, Steven Yang1, Chang Jie Mick Lee3,4, Chen Wang2, Caroline Chou1, Christoph Kuppe9, Kevin D. Cook2, Atilla Kovacs1, Vishnu Chintalgattu2, Danielle Pruitt2, Jose Barreda2, Nathan O. Stitziel1,10,11, Paul Cheng12,13, Yongjian Liu8, Rafael Kramann7,9,14, Daniel Kreisel15,16, Roger S.-Y. Foo3,4, Ingrid C. Rulifson2, Scott Martin2, David Grunert2, Melissa Thomas2, Jixin Cui2, Thomas Quertermous12,13, Frank M. Bengel6, Simon Jackson2, Chi-Ming Li2, Brandon Ason2, Kory J. Lavine1,15,17,18* Vascular smooth muscle cell (VSMC) diversification drives atherosclerotic coronary artery disease (CAD), but the mechanisms governing these cell state transitions remain unclear. …
摘自《科学》(Science)第392卷 第6793期 · 2026年4月2日。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。